Equities

Fusion Antibodies PLC

FAB:LSE

Fusion Antibodies PLC

Health CareHealth Care Providers
  • Price (GBX)3.65
  • Today's Change-0.10 / -2.67%
  • Shares traded167.78k
  • 1 Year change-89.26%
  • Beta0.5279
Data delayed at least 20 minutes, as of Apr 26 2024 16:10 BST.
More ▼

Profile data is unavailable for this security.

About the company

Fusion Antibodies plc is a United Kingdom-based collaborative research organization (CRO) company. The principal activity of the Company is the research, development, and manufacture of recombinant proteins and antibodies, particularly in the areas of cancer and infectious diseases. It is engaged in providing an integrated end-to-end range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications. It offers a range of services in antibody generation, development, characterization, optimization, and small-scale production. These services include antigen expression, purification and sequencing, antibody humanization using its proprietary CDRx platform and cell line development, producing antibody generating stable cell lines optimized for use downstream by the customer to produce material for clinical trials. It is also developing OptiMAL, a mammalian antibody library and discovery platform yielding fully human antibodies.

  • Revenue in GBP (TTM)1.58m
  • Net income in GBP-2.84m
  • Incorporated2000
  • Employees50.00
  • Location
    Fusion Antibodies PLCSpringbank Industrial Estate1 Springbank RoadBELFAST BT17 0QLUnited KingdomGBR
  • Phone+44 28 9043 2800Fax+44 28 9002 0446
  • Websitehttps://fusionantibodies.com/
More ▼

Peer analysis

CompanyRevenue (TTM)Net income (TTM)Market capEmployeesMarket Cap /
Employees
Nuformix PLC0.00-436.95k1.56m2.001.56m2.00
ReNeuron Group Plc249.00k-5.07m1.93m34.001.93m34.00
N4 Pharma PLC1.95k-1.28m2.08m5.002.08m5.00
TheraCryf PLC838.00k-3.35m3.42m7.003.42m7.00
Fusion Antibodies PLC1.58m-2.84m3.48m50.003.48m50.00
Hellenic Dynamics PLC-100.00bn-100.00bn3.69m25.003.69m25.00
Oxford Cannabinoid Tchnlgs Hldngs PLC0.00-4.24m3.97m7.003.97m7.00
IXICO PLC6.67m-1.18m4.18m89.004.18m89.00
ValiRx Plc0.00-2.41m4.43m8.004.43m8.00
Data as of Apr 26 2024. Currency figures normalised to Fusion Antibodies PLC's reporting currency: UK Pound GBX

Institutional shareholders

13.68%Per cent of shares held by top holders
HolderShares% Held
Unicorn Asset Management Ltd.as of 07 Mar 20246.40m6.71%
Rathbones Investment Management Ltd.as of 07 Mar 20244.51m4.73%
Octopus Investments Ltd.as of 12 Jun 20231.48m1.56%
Canaccord Genuity Wealth Ltd.as of 30 Sep 2023654.55k0.69%
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.